Inmune Bio Inc (INMB) Stock Price, Quote & News

Company Profile

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of br...

Industry: Biotechnology

Sector: Healthcare

Phone: 561 710 0512

Website: www.inmunebio.com

Address:

225 NE Mizner Blvd., Suite 640, Boca Raton, United States

NachoBusiness Aug. 21 at 8:56 PM

$INMB held well today.

0 · Reply

alexx013 Aug. 21 at 4:43 PM

$INMB nice

0 · Reply

zampy Aug. 21 at 12:25 AM

$INMB Hope this comes in more

0 · Reply

NachoBusiness Aug. 20 at 11:57 AM

$INMB Bid back at 2.19. Need a volume push.

0 · Reply

NachoBusiness Aug. 19 at 3:34 PM

$INMB 2.64 next pivot point

0 · Reply

alexx013 Aug. 19 at 3:01 PM

$INMB 2.19 busted, going north

1 · Reply

NachoBusiness Aug. 18 at 2:10 AM

$INMB 2.08 overnight 2.19 rejected again.

0 · Reply

NachoBusiness Aug. 17 at 3:28 PM

$INMB $2.19 hit again, lets see where it takes us. Could be a triple top , or a break of resistance.

0 · Reply

kenny91655 Aug. 14 at 7:19 PM

$INMB What does this do for RDEB?

0 · Reply

Muscle24 Aug. 14 at 4:24 PM

$INMB SUPER BULLISH!!!! What a beautiful chart!!!!

2 · Reply

INmune Bio Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 16 days ago

INmune Bio Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 16 days ago

INmune Bio Earnings release: Q2 2026

2026-07-31T11:05:59.000Z - 22 days ago

INmune Bio receives $4.6M in rebates from Australia, UK

Jul 31, 2026, 7:00 AM EDT - 22 days ago

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

Jul 31, 2026, 7:00 AM EDT - 22 days ago

INmune Bio Receives R&D Rebates of Approximately $4.6 Million

Jul 30, 2026, 7:00 AM EDT - 23 days ago

INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform

2026-07-20T11:05:18.000Z - 4 weeks ago

INmune Bio processes first umbilical cord tissue at CGT Catapult

Jul 20, 2026, 7:00 AM EDT - 4 weeks ago

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

Jul 15, 2026, 7:00 AM EDT - 5 weeks ago

INmune Bio's XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study

Jul 9, 2026, 7:00 AM EDT - 6 weeks ago

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC

2026-07-01T11:20:37.000Z - 7 weeks ago

INmune Bio advances CORDStrom platform patent application in the U.S.

Jul 1, 2026, 7:00 AM EDT - 7 weeks ago

INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

2026-06-25T11:15:15.000Z - 2 months ago

INmune Bio receives MHRA approval for Ebstrocel pediatric investigation plan

Jun 25, 2026, 7:00 AM EDT - 2 months ago

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

2026-06-23T16:47:42.000Z - 2 months ago

INmune Bio announces MHRA alignment in pre-MAA CORDStrom meeting

Jun 23, 2026, 8:00 AM EDT - 2 months ago

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

Jun 16, 2026, 10:00 AM EDT - 2 months ago

INmune Bio Transcript: AGM 2026

2026-06-02T14:35:32.000Z - 2 months ago

INmune Bio reports positive MRI data in Phase 2 Alzheimer’s trial

Jun 2, 2026, 8:00 AM EDT - 2 months ago

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial

Jun 2, 2026, 7:00 AM EDT - 2 months ago

INmune Bio Slides: Corporate presentation

2026-05-15T13:24:06.000Z - 3 months ago

INmune Bio publishes MINDFuL trial results in NPJ Dementia

May 15, 2026, 8:00 AM EDT - 3 months ago

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform

2026-05-14T14:59:02.000Z - 3 months ago

INmune Bio receives fast track designation from FDA for XPro

May 14, 2026, 8:00 AM EDT - 3 months ago

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease

May 13, 2026, 8:00 AM EDT - 3 months ago

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point

May 7, 2026, 4:30 PM EDT - 3 months ago

INmune Bio Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

INmune Bio Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

INmune Bio Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 3 months ago

INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update

May 5, 2026, 4:00 PM EDT - 3 months ago

INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases

Apr 30, 2026, 8:00 AM EDT - 4 months ago

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th

Apr 23, 2026, 8:00 AM EDT - 4 months ago

INmune Bio Proxy statement: Proxy filing

2026-04-16T14:16:48.000Z - 4 months ago

INmune Bio announces new preclinical data for INB03

Mar 30, 2026, 4:30 PM EDT - 5 months ago

INmune Bio Earnings Call Transcript: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 5 months ago

INmune Bio Annual report: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 5 months ago

INmune Bio Earnings release: Q4 2025

Mar 30, 2026, 4:00 PM EDT - 5 months ago

INmune Bio Inc. Announces 2025 Results and Provides Business Update

Mar 24, 2026, 8:00 AM EDT - 5 months ago

INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.

2026-03-19T12:37:41.000Z - 5 months ago

INmune Bio’s MINDFuL trial presented as succesful example in Alzheimer’s

2026-03-11T10:11:18.000Z - 5 months ago

INmune Bio upgraded to Buy from Neutral at Lucid Capital

Mar 10, 2026, 7:00 AM EDT - 5 months ago

INmune Bio Slides: Corporate presentation

Feb 26, 2026, 1:00 PM EST - 6 months ago

INmune Bio Transcript: Study update

Feb 23, 2026, 9:25 AM EST - 6 months ago

INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar

Feb 19, 2026, 12:15 PM EST - 6 months ago

INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB

2026-02-12T12:20:01.000Z - 6 months ago

INmune Bio announces FDA alignment on phase 2b/3 registration pathway

2026-02-10T13:12:07.000Z - 6 months ago

INmune Bio submits pre-submission package for CORDStrom with MHRA

Feb 10, 2026, 8:00 AM EST - 6 months ago

INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB

2026-01-27T14:30:16.000Z - 7 months ago

INmune Bio CEO says ‘well positioned for continued execution’

Jan 27, 2026, 9:25 AM EST - 7 months ago

INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives

2025-12-05T12:10:33.000Z - 9 months ago

INmune Bio publishes study on INmune’s CORDStrom platform

Dec 5, 2025, 7:00 AM EST - 9 months ago

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform

2025-12-01T13:20:57.000Z - 9 months ago

INmune Bio announces neuroimaging data from Phase 2 MINDFuL trial

Dec 1, 2025, 8:00 AM EST - 9 months ago

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients

Nov 18, 2025, 8:00 AM EST - 9 months ago

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

2025-10-30T20:46:45.000Z - 10 months ago

INmune Bio reports Q3 EPS (24c), consensus (32c)

Oct 30, 2025, 4:30 PM EDT - 10 months ago

INmune Bio Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 10 months ago

INmune Bio Earnings release: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 10 months ago

INmune Bio Quarterly report: Q3 2025

Oct 30, 2025, 4:05 PM EDT - 10 months ago

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

Oct 14, 2025, 8:00 AM EDT - 11 months ago

INmune Bio Proxy statement: Proxy Filing

Oct 14, 2025, 7:00 AM EDT - 11 months ago

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

Oct 3, 2025, 8:00 AM EDT - 11 months ago

INmune Bio Proxy statement: Proxy Filing

2025-09-29T12:20:16.000Z - 11 months ago

INmune Bio submits Phase 2 MINDFuL trial results to npj Dementia

2025-09-15T12:10:30.000Z - 1 year ago

INmune Bio completes first commercial manufacturing run of CORDStrom

2025-08-07T21:55:30.000Z - 1 year ago

INmune Bio CEO RJ Tesi retires, David Moss succeeds

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Slides: Q2 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

Jul 31, 2025, 7:00 AM EDT - 1 year ago

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

Jul 29, 2025, 7:00 AM EDT - 1 year ago

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

Jun 30, 2025, 4:05 PM EDT - 1 year ago

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 30, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Transcript: Status Update

Jun 30, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Press release: Status Update

Jun 30, 2025, 7:36 AM EDT - 1 year ago

INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study

Jun 30, 2025, 7:30 AM EDT - 1 year ago

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease

Jun 27, 2025, 12:16 PM EDT - 1 year ago

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 26, 2025, 4:00 PM EDT - 1 year ago

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th

May 9, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Proxy statement: Proxy Filing

May 8, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Quarterly report: Q1 2025

May 8, 2025, 4:10 PM EDT - 1 year ago

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

May 5, 2025, 7:00 AM EDT - 1 year ago

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

Apr 25, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

Apr 3, 2025, 7:00 AM EDT - 1 year ago

INmune Bio Slides: Corporate Presentation

Mar 27, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Annual report: Q4 2024

Mar 27, 2025, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Feb 12, 2025, 7:00 AM EST - 1 year ago

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

Feb 10, 2025, 8:30 AM EST - 1 year ago

INmune Bio Transcript: Study Result

Feb 10, 2025, 7:00 AM EST - 1 year ago

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Dec 4, 2024, 9:00 AM EST - 1 year ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

Oct 31, 2024, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

INmune Bio Quarterly report: Q3 2024

Oct 31, 2024, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

Oct 28, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

Oct 24, 2024, 3:03 PM EDT - 1 year ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Oct 24, 2024, 9:30 AM EDT - 1 year ago

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Oct 11, 2024, 8:30 AM EDT - 2 years ago

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

Sep 26, 2024, 8:00 AM EDT - 2 years ago

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

Sep 17, 2024, 8:30 AM EDT - 2 years ago

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

Sep 13, 2024, 8:30 AM EDT - 2 years ago

INmune Bio Announces $13.0 Million Registered Direct Offering

NachoBusiness Aug. 21 at 8:56 PM

$INMB held well today.

0 · Reply

alexx013 Aug. 21 at 4:43 PM

$INMB nice

0 · Reply

zampy Aug. 21 at 12:25 AM

$INMB Hope this comes in more

0 · Reply

NachoBusiness Aug. 20 at 11:57 AM

$INMB Bid back at 2.19. Need a volume push.

0 · Reply

NachoBusiness Aug. 19 at 3:34 PM

$INMB 2.64 next pivot point

0 · Reply

alexx013 Aug. 19 at 3:01 PM

$INMB 2.19 busted, going north

1 · Reply

NachoBusiness Aug. 18 at 2:10 AM

$INMB 2.08 overnight 2.19 rejected again.

0 · Reply

NachoBusiness Aug. 17 at 3:28 PM

$INMB $2.19 hit again, lets see where it takes us. Could be a triple top , or a break of resistance.

0 · Reply

kenny91655 Aug. 14 at 7:19 PM

$INMB What does this do for RDEB?

0 · Reply

Muscle24 Aug. 14 at 4:24 PM

$INMB SUPER BULLISH!!!! What a beautiful chart!!!!

2 · Reply

NachoBusiness Aug. 14 at 4:21 PM

$INMB 2.19 rejection again. Curious why

1 · Reply

10baggerPete Aug. 14 at 4:17 PM

$INMB super nice movement

0 · Reply

NachoBusiness Aug. 11 at 1:43 PM

$INMB This is the next zone that needs to break. Then we worry about $3.24

0 · Reply

NachoBusiness Aug. 10 at 3:36 PM

$INMB Retracement back to 1.96 seems likely per the chart. Bulls need to step in.

2 · Reply

NachoBusiness Aug. 10 at 3:34 PM

$INMB Textbook rejection at 2.19

2 · Reply

RunningRobert1 Aug. 10 at 3:24 PM

$INMB INmune Bio INMB Q2 2026 Summary 10Aug2026 https://youtu.be/96qx7pg5zGg So I like this stock, insiders own a decent amount of shares, and there is a good chance they will be getting a voucher which can be sold for 3x the current market cap. The biggest issue is getting to that point, as they will fall a bit short (money till 2Q 2027 approval would be 3Q 2027)

2 · Reply

NachoBusiness Aug. 10 at 3:04 PM

$INMB Could see a possible rejection here, same as last month.

0 · Reply

Muscle24 Aug. 10 at 2:48 PM

$INMB Loving the smart money accumulation!!!!

0 · Reply

NachoBusiness Aug. 10 at 2:09 PM

$INMB This is where it rejected last time 2.19, if we can run above this, we can see some clear daylight

0 · Reply

Muscle24 Aug. 8 at 3:32 PM

$INMB EXTREMELY SUPER DUPER BULLISHHHHH!!!!!!!

0 · Reply

zampy Aug. 8 at 12:18 AM

$INMB Great week!!! What is surprising the borrow rate is only 2.98%.

0 · Reply

daybaron Aug. 7 at 8:04 PM

$INMB there are serious interests in selling this below $2.10, discouraging, but next week is right near

1 · Reply

Market Cap	59.95M
Revenue (ttm)	50,000.00
Net Income (ttm)	-45.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-91,860.00%
Debt to Equity Ratio	0.00

Volume	520,100
Avg Vol	823,012
Day's Range	N/A - N/A
Shares Out	27.75M
Stochastic %K	94%
Beta	0.97
Analysts	Strong Sell
Price Target	$7.00